{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:31:09Z","timestamp":1793766669830,"version":"4.6.1"},"reference-count":145,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,13]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Significant progress in determining the molecular origins and resistance mechanisms of mantle cell lymphoma (MCL) has improved our understanding of the disease\u2019s clinical diversity. These factors greatly impact the prognosis of patients with MCL. Given the dynamic alterations in MCL clones and disease evolution, it is crucial to recognize high-risk prognostic factors at diagnosis and relapse. Clinical factors include a high MCL International Prognostic Index score with a high Ki-67 proliferation index, early disease progression within 24 months of first-line treatment, &amp;gt;3 previous lines of therapy at relapse, and an aggressive (blastoid or pleomorphic) histology. Molecular aberrations include dysregulated cyclin D1, an aberrant SOX11-CD70 axis, upregulated Musashi-2, MYC rearrangement, metabolic reprogramming, and epigenetic changes. Other factors that contribute to high-risk MCL include an immune-depleted microenvironment and clone adaptability with complex chromosomal anomalies and somatic mutations in TP53, NSD2, CCND1, CDKN2A, BIRC3, SP140, KMT2D, NFkBIE, SMARCA4, and NOTCH2. Ultra-high-risk MCL is indicated by the coexistence of multiple high-risk prognostic factors in the relapse setting and can portend very short progression-free survival. As MCL treatments advance toward cellular therapies, resistance to anti-CD19 chimeric antigen receptor T-cell therapy is also observed. These findings necessitate revisiting the prognostic impact of high-risk factors, current management strategies, new bi- and trispecific T-cell engagers, combination therapies, novel therapeutic targets, and next-generation clinical trials for patients with high-risk MCL. This article provides a comprehensive update on recognizing and managing high-risk MCL and encompass current practices and future directions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2023022354","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T14:05:41Z","timestamp":1735567541000},"page":"683-695","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":27,"title":["High-risk MCL: recognition and treatment"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2735-168X","authenticated-orcid":false,"given":"Preetesh","family":"Jain","sequence":"first","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9748-5486","authenticated-orcid":false,"given":"Michael","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2025032119374176900_bib1","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/ajh.26523","article-title":"Mantle cell lymphoma in\u00a02022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments","volume":"97","author":"Jain","year":"2022","journal-title":"Am J Hematol"},{"issue":"7","key":"2025032119374176900_bib2","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1182\/blood.2023022351","article-title":"Unraveling MCL biology to understand resistance and identify vulnerabilities","volume":"145","author":"Sarkozy","year":"2025","journal-title":"Blood"},{"issue":"6","key":"2025032119374176900_bib3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"10121","key":"2025032119374176900_bib4","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"issue":"16","key":"2025032119374176900_bib5","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1158\/1078-0432.CCR-19-3703","article-title":"Treatment of patients with relapsed or refractory mantle cell lymphoma with zanubrutinib, a selective inhibitor of Bruton's tyrosine kinase","volume":"26","author":"Song","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"24","key":"2025032119374176900_bib6","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1200\/JCO.23.00562","article-title":"Pirtobrutinib in covalent Bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2025032119374176900_bib7","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1182\/blood-2023-174416","article-title":"Obinutuzumab versus rituximab in transplant eligible untreated MCL patients, a matching comparison between the Lyma and Lyma-101 trials","volume":"142","author":"Sarkozy","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2025032119374176900_bib8","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1182\/blood-2023-180069","article-title":"A\u00a0multicenter phase 2 trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in patients with treatment-na\u00efve, TP53-mutant mantle cell lymphoma","volume":"142","author":"Kumar","year":"2023","journal-title":"Blood"},{"issue":"7","key":"2025032119374176900_bib9","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood.2020008727","article-title":"Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1\/2 trial","volume":"137","author":"Le Gouill","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2025032119374176900_bib10","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1182\/blood-2022-158656","article-title":"Phase 2 trial of acalabrutinib-lenalidomide-rituximab (ALR) with real-time monitoring of MRD in patients with treatment-na\u00efve mantle cell lymphoma","volume":"140","author":"Ruan","year":"2022","journal-title":"Blood"},{"issue":"11","key":"2025032119374176900_bib11","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1182\/bloodadvances.2021006934","article-title":"Survival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: a population-based analysis","volume":"6","author":"Di","year":"2022","journal-title":"Blood Adv"},{"issue":"36","key":"2025032119374176900_bib12","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1200\/JCO.20.02287","article-title":"High-risk mantle cell lymphoma: definition, current challenges, and management","volume":"38","author":"Jain","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2025032119374176900_bib13","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1097\/HS9.0000000000000510","article-title":"Detailed long-term follow-up of patients who relapsed after the Nordic mantle cell lymphoma trials: MCL2 and MCL3","volume":"5","author":"Eskelund","year":"2021","journal-title":"Hemasphere"},{"issue":"17","key":"2025032119374176900_bib14","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2025032119374176900_bib15","first-page":"1857","article-title":"Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group","volume":"109","author":"Carras","year":"2024","journal-title":"Haematologica"},{"issue":"9","key":"2025032119374176900_bib16","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1038\/s41375-023-01977-y","article-title":"Clinical outcome of mantle cell lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression)","volume":"37","author":"Scheubeck","year":"2023","journal-title":"Leukemia"},{"issue":"6","key":"2025032119374176900_bib17","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.3324\/haematol.2018.214056","article-title":"KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study","volume":"105","author":"Ferrero","year":"2020","journal-title":"Haematologica"},{"issue":"3","key":"2025032119374176900_bib18","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14241","article-title":"15-year follow-up of the second Nordic mantle cell lymphoma trial (MCL2): prolonged remissions without survival plateau","volume":"175","author":"Eskelund","year":"2016","journal-title":"Br J Haematol"},{"issue":"1","key":"2025032119374176900_bib19","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/bjh.13796","article-title":"Rituximab plus hyper-CVAD alternating with MTX\/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center","volume":"172","author":"Chihara","year":"2016","journal-title":"Br J Haematol"},{"issue":"5","key":"2025032119374176900_bib20","doi-asserted-by":"crossref","first-page":"e712","DOI":"10.1097\/HS9.0000000000000712","article-title":"Long-term outcomes with ibrutinib treatment for patients with relapsed\/refractory mantle cell lymphoma: a pooled analysis of 3 clinical trials with nearly 10 years of follow-up","volume":"6","author":"Dreyling","year":"2022","journal-title":"Hemasphere"},{"issue":"21","key":"2025032119374176900_bib21","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.2021014162","article-title":"Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study","volume":"139","author":"Song","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2025032119374176900_bib22","first-page":"343","article-title":"Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed\/refractory mantle cell lymphoma, including those with poor prognostic factors","volume":"109","author":"Le Gouill","year":"2024","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2025032119374176900_bib23","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2023-181627","article-title":"Pirtobrutinib in relapsed\/refractory (R\/R) mantle cell lymphoma (MCL) patients with prior cBTKi: safety and efficacy including high-risk subgroup analyses from the phase 1\/2 BRUIN study","volume":"142","author":"Cohen","year":"2023","journal-title":"Blood"},{"issue":"23","key":"2025032119374176900_bib24","doi-asserted-by":"crossref","first-page":"5179","DOI":"10.1182\/bloodadvances.2021004765","article-title":"Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy","volume":"5","author":"Bond","year":"2021","journal-title":"Blood Adv"},{"issue":"5","key":"2025032119374176900_bib25","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/bjh.15643","article-title":"Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death","volume":"185","author":"Visco","year":"2019","journal-title":"Br J Haematol"},{"issue":"16","key":"2025032119374176900_bib26","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/bloodadvances.2023009804","article-title":"Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed\/refractory mantle cell lymphoma","volume":"7","author":"Villa","year":"2023","journal-title":"Blood Adv"},{"issue":"4","key":"2025032119374176900_bib27","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/bjh.15567","article-title":"Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib","volume":"183","author":"Jain","year":"2018","journal-title":"Br J Haematol"},{"issue":"6","key":"2025032119374176900_bib28","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/ajh.25796","article-title":"Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients","volume":"95","author":"Zhao","year":"2020","journal-title":"Am J Hematol"},{"issue":"14","key":"2025032119374176900_bib29","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2025032119374176900_bib30","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2025032119374176900_bib31","doi-asserted-by":"crossref","first-page":"E137","DOI":"10.1002\/ajh.26109","article-title":"Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib","volume":"96","author":"Jain","year":"2021","journal-title":"Am J Hematol"},{"issue":"3","key":"2025032119374176900_bib32","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"41","author":"Wang","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2025032119374176900_bib33","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1111\/bjh.17197","article-title":"Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy","volume":"192","author":"Jain","year":"2021","journal-title":"Br J Haematol"},{"issue":"1","key":"2025032119374176900_bib34","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12943-022-01655-0","article-title":"TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma","volume":"21","author":"Jiang","year":"2022","journal-title":"Mol Cancer"},{"issue":"suppl\u00a01","key":"2025032119374176900_bib35","doi-asserted-by":"crossref","first-page":"S462","DOI":"10.1016\/S2152-2650(23)01378-2","article-title":"MCL-467 glofitamab monotherapy induces high complete response rates in patients with heavily pretreated relapsed or refractory mantle cell lymphoma","volume":"23","author":"Phillips","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"2025032119374176900_bib36","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.23.02470","article-title":"Glofitamab in relapsed\/refractory mantle cell lymphoma: results from a phase\u00a0I\/II study","volume":"43","author":"Phillips","year":"2025","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"2025032119374176900_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2022-163018","article-title":"Efficacy and safety of ibrutinib combined with standard first-line treatment or as substitute for autologous stem cell transplantation in younger patients with mantle cell lymphoma: results from the\u00a0randomized triangle trial by the European MCL network","volume":"140","author":"Dreyling","year":"2022","journal-title":"Blood"},{"issue":"8","key":"2025032119374176900_bib38","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/blood.2023021306","article-title":"CAR T cells and time-limited ibrutinib as treatment for relapsed\/refractory mantle cell lymphoma: the phase 2 TARMAC study","volume":"143","author":"Minson","year":"2024","journal-title":"Blood"},{"issue":"10","key":"2025032119374176900_bib39","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s11912-022-01286-0","article-title":"BTK inhibitors and CAR T-cell therapy in treating mantle cell lymphoma-finding a dancing partner","volume":"24","author":"Munoz","year":"2022","journal-title":"Curr Oncol Rep"},{"issue":"6","key":"2025032119374176900_bib40","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/bloodadvances.2019001396","article-title":"Genomic profiles and clinical outcomes of de novo blastoid\/pleomorphic MCL are distinct from those of transformed MCL","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2025032119374176900_bib41","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/blood-2023-189505","article-title":"Ki-67 expression of 50% is the optimal cut-off to predict survival outcomes in mantle cell lymphoma (MCL): a pooled analysis from CALGB 50403 (alliance) and MCL real-world study cohort","volume":"142","author":"Epperla","year":"2023","journal-title":"Blood"},{"issue":"12","key":"2025032119374176900_bib42","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1038\/s41375-024-02375-8","article-title":"Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in mantle cell lymphoma: results from the EU-MCL network trials","volume":"38","author":"Khouja","year":"2024","journal-title":"Leukemia"},{"issue":"8","key":"2025032119374176900_bib43","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/annonc\/mdt139","article-title":"Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network","volume":"24","author":"Cheah","year":"2013","journal-title":"Ann Oncol"},{"issue":"13","key":"2025032119374176900_bib44","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1182\/bloodadvances.2019001350","article-title":"Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis","volume":"4","author":"Hill","year":"2020","journal-title":"Blood Adv"},{"issue":"11","key":"2025032119374176900_bib45","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1002\/cncr.31328","article-title":"Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy","volume":"124","author":"Greenwell","year":"2018","journal-title":"Cancer"},{"issue":"5","key":"2025032119374176900_bib46","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.3324\/haematol.2019.243071","article-title":"MYC rearrangement but not extra MYC copies is an independent prognostic factor in patients with mantle cell lymphoma","volume":"106","author":"Wang","year":"2020","journal-title":"Haematologica"},{"issue":"3","key":"2025032119374176900_bib47","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/his.12760","article-title":"MYC overexpression correlates with MYC amplification or translocation, and is associated with poor prognosis in mantle cell lymphoma","volume":"68","author":"Choe","year":"2016","journal-title":"Histopathology"},{"issue":"16","key":"2025032119374176900_bib48","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1182\/bloodadvances.2018016048","article-title":"Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma","volume":"2","author":"Lee","year":"2018","journal-title":"Blood Adv"},{"issue":"2","key":"2025032119374176900_bib49","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/PAS.0000000000000758","article-title":"Mantle cell lymphoma with MYC rearrangement: a report of 17 patients","volume":"41","author":"Hu","year":"2017","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"2025032119374176900_bib50","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1046\/j.1365-2141.2003.04121.x","article-title":"Abnormal expression of apoptosis-related genes in haematological malignancies: overexpression of MYC is poor prognostic sign in mantle cell lymphoma","volume":"120","author":"Nagy","year":"2003","journal-title":"Br J Haematol"},{"issue":"2","key":"2025032119374176900_bib51","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A\u00a0new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"issue":"6","key":"2025032119374176900_bib52","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41408-019-0209-5","article-title":"Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse","volume":"9","author":"Kumar","year":"2019","journal-title":"Blood Cancer J"},{"issue":"10","key":"2025032119374176900_bib53","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/ajh.27044","article-title":"Sequencing-based analysis of clonal evolution of 25 mantle cell lymphoma patients at diagnosis and after failure of standard immunochemotherapy","volume":"98","author":"Karolova","year":"2023","journal-title":"Am J Hematol"},{"issue":"4","key":"2025032119374176900_bib54","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1182\/blood-2018-05-851667","article-title":"Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma","volume":"133","author":"Mohanty","year":"2019","journal-title":"Blood"},{"issue":"22","key":"2025032119374176900_bib55","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1182\/blood.2020010527","article-title":"SOX11, CD70, and Treg cells configure the tumor-immune microenvironment of aggressive mantle cell lymphoma","volume":"138","author":"Balsas","year":"2021","journal-title":"Blood"},{"issue":"2","key":"2025032119374176900_bib56","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/s41375-022-01776-x","article-title":"Tumorigenic role of Musashi-2 in aggressive mantle cell lymphoma","volume":"37","author":"Sureda-Gomez","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"2025032119374176900_bib57","doi-asserted-by":"crossref","first-page":"7863","DOI":"10.1038\/s41598-024-58216-2","article-title":"SOX11\/PRDX2 axis modulates redox homeostasis and chemoresistance in aggressive mantle cell lymphoma","volume":"14","author":"De Bolos","year":"2024","journal-title":"Sci Rep"},{"issue":"5","key":"2025032119374176900_bib58","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.ccell.2016.09.014","article-title":"Decoding the DNA methylome of mantle cell lymphoma in the light of the entire B cell lineage","volume":"30","author":"Queiros","year":"2016","journal-title":"Cancer Cell"},{"issue":"3","key":"2025032119374176900_bib59","doi-asserted-by":"crossref","first-page":"e153283","DOI":"10.1172\/JCI153283","article-title":"Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma","volume":"132","author":"Yi","year":"2022","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"2025032119374176900_bib60","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","article-title":"Pharmacological and genomic profiling identifies NF-\u03baB-targeted treatment strategies for mantle cell lymphoma","volume":"20","author":"Rahal","year":"2014","journal-title":"Nat Med"},{"issue":"1","key":"2025032119374176900_bib61","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","article-title":"Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma","volume":"25","author":"Agarwal","year":"2019","journal-title":"Nat Med"},{"issue":"45","key":"2025032119374176900_bib62","doi-asserted-by":"crossref","first-page":"73558","DOI":"10.18632\/oncotarget.12434","article-title":"CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma","volume":"7","author":"Mohanty","year":"2016","journal-title":"Oncotarget"},{"issue":"5-6","key":"2025032119374176900_bib63","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41417-018-0022-5","article-title":"Genomic landscape and prognostic analysis of mantle cell lymphoma","volume":"25","author":"Yang","year":"2018","journal-title":"Cancer Gene Ther"},{"issue":"9","key":"2025032119374176900_bib64","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1182\/blood-2011-11-391474","article-title":"Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma","volume":"119","author":"Kridel","year":"2012","journal-title":"Blood"},{"issue":"45","key":"2025032119374176900_bib65","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.1073\/pnas.1314608110","article-title":"Landscape of somatic mutations and clonal evolution in mantle cell lymphoma","volume":"110","author":"Bea","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2025032119374176900_bib66","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1182\/blood.V89.1.272","article-title":"Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas","volume":"89","author":"Pinyol","year":"1997","journal-title":"Blood"},{"issue":"20","key":"2025032119374176900_bib67","first-page":"4608","article-title":"Alterations of the cyclin D1\/p16-pRB pathway in mantle cell lymphoma","volume":"57","author":"Dreyling","year":"1997","journal-title":"Cancer Res"},{"issue":"8","key":"2025032119374176900_bib68","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/gcc.22849","article-title":"Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A\/B loss, and TP53 mutations: a multi-institutional study","volume":"59","author":"Streich","year":"2020","journal-title":"Genes Chromosomes Cancer"},{"issue":"1","key":"2025032119374176900_bib69","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41408-023-00927-2","article-title":"Immune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma","volume":"13","author":"Jain","year":"2023","journal-title":"Blood Cancer J"},{"issue":"1","key":"2025032119374176900_bib70","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/bjh.16317","article-title":"Comorbidities and sex differences in causes of death among mantle cell lymphoma patients - a nationwide population-based cohort study","volume":"189","author":"Glimelius","year":"2020","journal-title":"Br J Haematol"},{"issue":"11","key":"2025032119374176900_bib71","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1182\/bloodadvances.2022009225","article-title":"Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma","volume":"7","author":"Epperla","year":"2023","journal-title":"Blood Adv"},{"issue":"12","key":"2025032119374176900_bib72","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","article-title":"Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European Mantle Cell Lymphoma Network","volume":"34","author":"Hoster","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2025032119374176900_bib73","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.hoc.2020.06.009","article-title":"Blastoid mantle cell lymphoma","volume":"34","author":"Jain","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"issue":"2","key":"2025032119374176900_bib74","first-page":"103","article-title":"Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network","volume":"2","author":"Klapper","year":"2009","journal-title":"J\u00a0Hematop"},{"issue":"1","key":"2025032119374176900_bib75","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/gcc.22123","article-title":"Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index","volume":"53","author":"Sarkozy","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"issue":"10","key":"2025032119374176900_bib76","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1182\/blood.V87.10.4302.bloodjournal87104302","article-title":"p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis","volume":"87","author":"Greiner","year":"1996","journal-title":"Blood"},{"issue":"8","key":"2025032119374176900_bib77","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1182\/blood.V87.8.3351.bloodjournal8783351","article-title":"p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas","volume":"87","author":"Hernandez","year":"1996","journal-title":"Blood"},{"issue":"12","key":"2025032119374176900_bib78","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/leu.2011.162","article-title":"Impact of TP53 mutation and 17p deletion in mantle cell lymphoma","volume":"25","author":"Halldorsdottir","year":"2011","journal-title":"Leukemia"},{"issue":"11","key":"2025032119374176900_bib79","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.clml.2018.07.282","article-title":"TP53 mutation and complex karyotype portends a dismal prognosis in patients with mantle cell lymphoma","volume":"18","author":"Obr","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"2025032119374176900_bib80","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1182\/blood-2017-07-797019","article-title":"Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network","volume":"131","author":"Aukema","year":"2018","journal-title":"Blood"},{"issue":"18","key":"2025032119374176900_bib81","doi-asserted-by":"crossref","first-page":"18643","DOI":"10.1002\/cam4.6473","article-title":"Long-term outcomes of second-line versus later-line zanubrutinib treatment in patients with relapsed\/refractory mantle cell lymphoma: an updated pooled analysis","volume":"12","author":"Song","year":"2023","journal-title":"Cancer Med"},{"issue":"20","key":"2025032119374176900_bib82","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1182\/blood.2022016953","article-title":"Ventricular arrhythmias and sudden death events following acalabrutinib initiation","volume":"140","author":"Bhat","year":"2022","journal-title":"Blood"},{"issue":"10","key":"2025032119374176900_bib83","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1182\/bloodadvances.2023011641","article-title":"Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib","volume":"8","author":"Moslehi","year":"2024","journal-title":"Blood Adv"},{"issue":"31","key":"2025032119374176900_bib84","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1200\/JCO.21.00693","article-title":"Cardiovascular risk associated with ibrutinib use in chronic lymphocytic leukemia: a population-based cohort study","volume":"39","author":"Abdel-Qadir","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"2025032119374176900_bib85","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","article-title":"Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma","volume":"386","author":"Wang","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2025032119374176900_bib86","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.3324\/haematol.2018.198812","article-title":"Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy","volume":"104","author":"Eyre","year":"2019","journal-title":"Haematologica"},{"issue":"suppl 2","key":"2025032119374176900_bib87","first-page":"LBA-2-LBA-2","article-title":"Ibrutinib combined with venetoclax in patients with relapsed\/refractory mantle cell lymphoma: primary analysis results from the randomized phase 3 Sympatico study","volume":"142","author":"Wang","year":"2023","journal-title":"Blood"},{"issue":"3","key":"2025032119374176900_bib88","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2217\/fon-2020-0794","article-title":"A\u00a0phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma","volume":"17","author":"Dreyling","year":"2021","journal-title":"Future Oncol"},{"issue":"2","key":"2025032119374176900_bib89","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.21.01797","article-title":"Ibrutinib with rituximab in first-line treatment of older patients with mantle cell lymphoma","volume":"40","author":"Jain","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2025032119374176900_bib90","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1182\/blood.V89.4.1421","article-title":"Blastoid variants of mantle cell lymphoma: frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones","volume":"89","author":"Ott","year":"1997","journal-title":"Blood"},{"issue":"26","key":"2025032119374176900_bib91","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1182\/blood-2017-08-737502","article-title":"Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge","volume":"132","author":"Dreyling","year":"2018","journal-title":"Blood"},{"issue":"24","key":"2025032119374176900_bib92","doi-asserted-by":"crossref","first-page":"7393","DOI":"10.1182\/bloodadvances.2023010757","article-title":"Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma","volume":"7","author":"Gerson","year":"2023","journal-title":"Blood Adv"},{"issue":"8","key":"2025032119374176900_bib93","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1097\/PAS.0000000000002068","article-title":"Blastoid and pleomorphic mantle cell lymphoma demonstrate distinct clinicopathologic and genetic features","volume":"47","author":"Khanlari","year":"2023","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"2025032119374176900_bib94","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/bjh.14870","article-title":"Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies","volume":"179","author":"Rule","year":"2017","journal-title":"Br J Haematol"},{"issue":"3","key":"2025032119374176900_bib95","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/bjh.15411","article-title":"Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed\/refractory mantle cell lymphoma (MCL)","volume":"182","author":"Jain","year":"2018","journal-title":"Br J Haematol"},{"issue":"491","key":"2025032119374176900_bib96","doi-asserted-by":"crossref","first-page":"eaau1167","DOI":"10.1126\/scitranslmed.aau1167","article-title":"Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma","volume":"11","author":"Zhang","year":"2019","journal-title":"Sci Transl Med"},{"issue":"suppl 1","key":"2025032119374176900_bib97","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1182\/blood-2023-179169","article-title":"Rituximab, bendamustine and cytarabine followed by venetoclax (V-RBAC) in high-risk older patients with mantle cell lymphoma: a phase 2 study by the Fondazione Italiana Linfomi (FIL)","volume":"142","author":"Visco","year":"2023","journal-title":"Blood"},{"issue":"10441","key":"2025032119374176900_bib98","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","article-title":"Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network","volume":"403","author":"Dreyling","year":"2024","journal-title":"Lancet"},{"issue":"3","key":"2025032119374176900_bib99","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S1470-2045(21)00638-0","article-title":"Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (\u226465 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial","volume":"23","author":"Wang","year":"2022","journal-title":"Lancet Oncol"},{"issue":"S2","key":"2025032119374176900_bib100","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/hon.3163_101","article-title":"Ibrutinib-rituximab and venetoclax (IRV) followed by risk-stratified R-hyperCVAD\/MTX in young patients with untreated mantle cell lymphoma\u2014phase-II WINDOW-2 trial","volume":"41","author":"Wang","year":"2023","journal-title":"Hematol Oncol"},{"issue":"13","key":"2025032119374176900_bib101","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1200\/JCO.2013.52.2466","article-title":"Confirmation of the mantle-cell lymphoma international prognostic index in randomized trials of the European Mantle-Cell Lymphoma Network","volume":"32","author":"Hoster","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2025032119374176900_bib102","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/bjh.19153","article-title":"Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine-rituximab","volume":"204","author":"Ramsower","year":"2024","journal-title":"Br J Haematol"},{"issue":"2","key":"2025032119374176900_bib103","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/S2352-3026(22)00355-6","article-title":"Treatment approaches for patients with TP53-mutated mantle cell lymphoma","volume":"10","author":"Lew","year":"2023","journal-title":"Lancet Haematol"},{"issue":"10","key":"2025032119374176900_bib104","doi-asserted-by":"crossref","first-page":"e6296","DOI":"10.1002\/ccr3.6296","article-title":"Mutant TP53 driving the Warburg effect in mantle cell lymphoma","volume":"10","author":"Kliebhan","year":"2022","journal-title":"Clin Case Rep"},{"issue":"suppl 1","key":"2025032119374176900_bib105","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1182\/blood-2023-187599","article-title":"Predicted functional consequences of TP53 alterations and prognosis in TP53-mutated mantle cell lymphoma","volume":"142","author":"Uppal","year":"2023","journal-title":"Blood"},{"issue":"suppl_1","key":"2025032119374176900_bib106","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood-2019-126619","article-title":"Three year update of the phase II ABT-199 (venetoclax) and ibrutinib in mantle cell lymphoma (AIM) study","volume":"134","author":"Handunnetti","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2025032119374176900_bib107","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/s41375-020-01119-8","article-title":"Correction: outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study","volume":"35","author":"Visco","year":"2021","journal-title":"Leukemia"},{"issue":"12","key":"2025032119374176900_bib108","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1182\/blood.2020005289","article-title":"Genomic and epigenomic insights into the origin, pathogenesis and clinical behavior of mantle cell lymphoma subtypes","volume":"136","author":"Nadeu","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"2025032119374176900_bib109","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood-2020-137473","article-title":"Complex karyotype is a significant predictor for worst outcomes in patients with mantle cell lymphoma (MCL) treated with BTK inhibitors - comprehensive analysis of 396 patients","volume":"136","author":"Jain","year":"2020","journal-title":"Blood"},{"issue":"22","key":"2025032119374176900_bib110","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1182\/blood.V128.22.1227.1227","article-title":"Production of anti-CD19 CAR T cells for ZUMA-3 and -4: phase 1\/2 multicenter studies evaluating KTE-C19 in patients with relapsed\/refractory B-precursor acute lymphoblastic leukemia (R\/R ALL)","volume":"128","author":"Sabatino","year":"2016","journal-title":"Blood"},{"issue":"14","key":"2025032119374176900_bib111","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.22.01797","article-title":"Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US Lymphoma CAR T Consortium","volume":"41","author":"Wang","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"2025032119374176900_bib112","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1182\/blood-2023-179269","article-title":"Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory (R\/R) mantle cell lymphoma (MCL): a CIBMTR subgroup analysis of high-risk characteristics","volume":"142","author":"Kambhampati","year":"2023","journal-title":"Blood"},{"issue":"5","key":"2025032119374176900_bib113","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1080\/10428194.2024.2304622","article-title":"Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement","volume":"65","author":"Lionel","year":"2024","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2025032119374176900_bib114","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/10428194.2023.2268228","article-title":"Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed\/refractory mantle cell lymphoma","volume":"65","author":"Hess","year":"2024","journal-title":"Leuk Lymphoma"},{"issue":"S2","key":"2025032119374176900_bib115","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/hon.3163_45","article-title":"Phase 2 study of anbal-cel, novel anti-CD19 CAR-T therapy with dual silencing of PD-1 and TIGIT in relapsed or refractory large B cell lymphoma - interim analysis result","volume":"41","author":"Kim","year":"2023","journal-title":"Hematol Oncol"},{"issue":"10","key":"2025032119374176900_bib116","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1200\/JCO.23.02214","article-title":"Lisocabtagene maraleucel in relapsed\/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study","volume":"42","author":"Wang","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"2025032119374176900_bib117","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1182\/blood-2023-173954","article-title":"Adaptive manufacturing of LV20.19 CAR T-cells for relapsed, refractory mantle cell lymphoma","volume":"142","author":"Shah","year":"2023","journal-title":"Blood"},{"issue":"6","key":"2025032119374176900_bib118","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2025032119374176900_bib119","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-019-0737-3","article-title":"Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma","volume":"26","author":"Brudno","year":"2020","journal-title":"Nat Med"},{"issue":"suppl 1","key":"2025032119374176900_bib120","doi-asserted-by":"crossref","first-page":"4857","DOI":"10.1182\/blood-2023-180989","article-title":"Trial-in-progress: a phase 1\/2 multi-center study of Onct-808, a ROR1-specific CAR T, in adult patients with relapsed\/refractory aggressive B cell lymphoma","volume":"142","author":"Wang","year":"2023","journal-title":"Blood"},{"issue":"23","key":"2025032119374176900_bib121","doi-asserted-by":"crossref","first-page":"7046","DOI":"10.1158\/1078-0432.CCR-19-1337","article-title":"Chimeric antigen receptor T cells targeting CD79b show efficacy in lymphoma with or without cotargeting CD19","volume":"25","author":"Ormhoj","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"511","key":"2025032119374176900_bib122","doi-asserted-by":"crossref","first-page":"eaaw9414","DOI":"10.1126\/scitranslmed.aaw9414","article-title":"CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies","volume":"11","author":"Qin","year":"2019","journal-title":"Sci Transl Med"},{"issue":"11","key":"2025032119374176900_bib123","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1080\/10428194.2023.2241095","article-title":"Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in TP53-mutated disease","volume":"64","author":"Lew","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2025032119374176900_bib124","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/bjh.15721","article-title":"Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations","volume":"184","author":"Lin","year":"2019","journal-title":"Br J Haematol"},{"issue":"12","key":"2025032119374176900_bib125","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.jtct.2023.09.008","article-title":"Long-term survivors after failure of chimeric antigen receptor T cell therapy for large B cell lymphoma: a role for allogeneic hematopoietic cell transplantation? A German Lymphoma Alliance and German Registry for stem cell transplantation analysis","volume":"29","author":"Derigs","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"2025032119374176900_bib126","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1182\/blood.2024024168","article-title":"Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma","volume":"144","author":"Godfrey","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2025032119374176900_bib127","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2023-179776","article-title":"Molecular mechanisms underlying response and resistance to glofitamab","volume":"142","author":"Nassiri","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2025032119374176900_bib128","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood-2023-174956","article-title":"Fixed duration mosunetuzumab plus polatuzumab vedotin has promising efficacy and a manageable safety profile in patients with BTKi relapsed\/refractory mantle cell lymphoma: initial results from a phase Ib\/II study","volume":"142","author":"Wang","year":"2023","journal-title":"Blood"},{"issue":"13","key":"2025032119374176900_bib129","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1182\/blood.2023022993","article-title":"Degraders upgraded: the rise of PROTACs in hematological malignancies","volume":"143","author":"Casan","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2025032119374176900_bib130","doi-asserted-by":"crossref","first-page":"9318","DOI":"10.1182\/blood-2022-158695","article-title":"Results from a phase 1\/2 study of tandem, bispecific anti-CD20\/anti-CD19 (LV20.19) CAR T-cells for mantle cell lymphoma","volume":"140","author":"Shah","year":"2022","journal-title":"Blood"},{"issue":"10","key":"2025032119374176900_bib131","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1158\/2159-8290.CD-21-1026","article-title":"Modulation of BCL-2 in both T cells and tumor cells to enhance chimeric antigen receptor T-cell immunotherapy against cancer","volume":"12","author":"Lee","year":"2022","journal-title":"Cancer Discov"},{"issue":"8010","key":"2025032119374176900_bib132","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41586-024-07242-1","article-title":"FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy","volume":"629","author":"Chan","year":"2024","journal-title":"Nature"},{"issue":"10","key":"2025032119374176900_bib133","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood.2022019419","article-title":"PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma","volume":"142","author":"Sloan","year":"2023","journal-title":"Blood"},{"issue":"18","key":"2025032119374176900_bib134","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1182\/blood.2023019706","article-title":"Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax resistance in preclinical models of hematologic malignancy","volume":"143","author":"Liu","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2025032119374176900_bib135","doi-asserted-by":"crossref","first-page":"7143","DOI":"10.1182\/blood-2023-174964","article-title":"Preclinical studies support the clinical development of LP-284 in relapsed and refractory B-cell lymphomas","volume":"142","author":"Zhou","year":"2023","journal-title":"Blood"},{"issue":"7","key":"2025032119374176900_bib136","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/s41375-024-02207-9","article-title":"The dual HCK\/BTK inhibitor KIN-8194 impairs growth and integrin-mediated adhesion of BTKi-resistant mantle cell lymphoma","volume":"38","author":"Lantermans","year":"2024","journal-title":"Leukemia"},{"issue":"3","key":"2025032119374176900_bib137","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41419-022-04684-1","article-title":"Dual BTK\/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma","volume":"13","author":"Thieme","year":"2022","journal-title":"Cell Death Dis"},{"issue":"3","key":"2025032119374176900_bib138","doi-asserted-by":"crossref","first-page":"e165694","DOI":"10.1172\/JCI165694","article-title":"Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma","volume":"133","author":"Jiang","year":"2023","journal-title":"J\u00a0Clin Invest"},{"issue":"4","key":"2025032119374176900_bib139","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/s41375-021-01477-x","article-title":"CD19\/BAFF-R dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute lymphoblastic leukemia","volume":"36","author":"Wang","year":"2022","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2025032119374176900_bib140","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1182\/blood-2023-188607","article-title":"Time limited exposure to a ROR1 targeting bispecific T cell engager (NVG-111) leads to durable responses in subjects with relapsed refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL)","volume":"142","author":"Townsend","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2025032119374176900_bib141","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1182\/blood-2021-148607","article-title":"Phase 1 dose escalation and cohort expansion study of the anti-ROR1 antibody-drug conjugate zilovertamab vedotin (MK-2140) for the treatment of non-Hodgkin lymphoma","volume":"138","author":"Wang","year":"2021","journal-title":"Blood"},{"issue":"S2","key":"2025032119374176900_bib142","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/hon.3163_99","article-title":"Acalabrutinib with rituximab as first-line therapy for older patients with mantle cell lymphona\u2014a phase II clinical trial","volume":"41","author":"Jain","year":"2023","journal-title":"Hematol Oncol"},{"issue":"17","key":"2025032119374176900_bib143","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1182\/blood.2022015560","article-title":"Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse","volume":"140","author":"Rusconi","year":"2022","journal-title":"Blood"},{"key":"2025032119374176900_bib144","doi-asserted-by":"crossref","first-page":"760405","DOI":"10.3389\/fonc.2021.760405","article-title":"Preliminary evaluation of zanubrutinib-containing regimens in DLBCL and the cerebrospinal fluid distribution of zanubrutinib: a 13-case series","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"issue":"5","key":"2025032119374176900_bib145","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.hoc.2020.06.006","article-title":"Minimal residual disease in mantle cell lymphoma: methods and clinical significance","volume":"34","author":"Ladetto","year":"2020","journal-title":"Hematol Oncol Clin North Am"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/7\/683\/2355540\/blood_bld-2023-022354-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/7\/683\/2355540\/blood_bld-2023-022354-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T16:18:02Z","timestamp":1742573882000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/7\/683\/534861\/High-risk-MCL-recognition-and-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":145,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,2,13]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023022354","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,13]]}}}